Current challenges in the development of acellular hemoglobin oxygen carriers by protein engineering

Shock

Volumn 52, Issue 1S, 2019, Pages 28-40

  Benitez Cardenas, Andres S ^a   Samuel, Premila P ^a   Olson, John S ^a  

^a RICE UNIVERSITY   (United States)

Author keywords

Autooxidation; blood substitutes; globin unfolding; hemin loss; hemoglobin toxicity; hemoglobin based oxygen carriers (HBOCs); NO scavenging; oxygen affinity

Indexed keywords

DIMER; GLOBIN; HAPTOGLOBIN; HEME; HEMIN; HEMOGLOBIN; NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE; BLOOD SUBSTITUTE;

ANTIOXIDANT ACTIVITY; BIOCHEMICAL ANALYSIS; ENDOTHELIUM CELL; ERYTHROCYTE; HUMAN; KIDNEY INJURY; MACROPHAGE ACTIVATION; OXIDATION; OXYGEN TRANSPORT; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; ANIMAL; BLOOD; METABOLISM; PROCEDURES;

ANIMALS; BLOOD SUBSTITUTES; HEMOGLOBINS; HUMANS; OXYGEN; PROTEIN ENGINEERING;

EID: 85065127266     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000001053     Document Type: Review

References (93)

1. Alayash AI: Mechanisms of toxicity and modulation of hemoglobin-based oxygen carriers (HBOCs). Shock 52(Suppl. 1):41-49, 2019.
2. Amberson W, Mulder A, Steggerda F, Flexner J, Pankratz D: Mammalian life without red blood corpuscles. Science 78:106-107, 1933.
3. Winslow RM: Chapter 1: Historical background. In:Winslow RM, editor. Blood Substitutes. San Diego, CA: Academic Press; 2006. pp. 5-16.
4. Amberson WR: Blood substitutes. Biol Rev 12(1):48-86, 1937.
5. Varnado CL, Mollan TL, Birukou I, Smith BJ, Henderson DP, Olson JS: Development of recombinant hemoglobin-based oxygen carriers. Antioxid Redox Signal 18(17):2314-2328, 2013.
6. Santry HP, Alam HB: Fluid resuscitation: Past, present, and the future. Shock 33(3):229-241, 2010.
7. Jahr JS, Nesargi SB, Lewis K, Johnson C: Blood substitutes and oxygen therapeutics: An overview and current status. Am J Ther 9(5):437-443, 2002.
8. Alayash AI: Setbacks in blood substitutes research and development: A biochemical perspective. Clin Lab Med 30(2):381-389, 2010.
9. Buehler PW, D'Agnillo F, Schaer DJ: Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. Trends Mol Med 16(10):447-457, 2010.
10. Alayash AI: Blood substitutes: Why haven't we been more successful Trends Biotechnol 32(4):177-185, 2014.
11. Weiskopf RB: Hemoglobin-based oxygen carriers: Disclosed history and theway ahead: The relativity of safety. Anesth Analg 119(4):758-760, 2014.
12. Moore EE, Johnson JL, Cheng AM, Masuno T, Banerjee A: Insights from studies of blood substitutes in trauma. Shock 24(3):197-205, 2005.
13. Bunn HF, Esham WT, Bull RW: The renal handling of hemoglobin. I. Glomerular filtration. J Exp Med 129(5):909-923, 1969.
14. Bunn HF, Jandl JH: The renal handling of hemoglobin. II. Catabolism. J Exp Med 129(5):925-934, 1969.
15. Baek JH, D'Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y, Schaer DJ, Buehler PW: Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 122(4):1444-1458, 2012.
16. Weiskopf RB: The efficacy and safety of liquid stored blood and storage duration: A confused subject; are patients confused Anesth Analg 119(2):224-229, 2014.
17. Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, Schaffner A: CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107(1):373-380, 2006.
18. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM: Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 121(8):1276-1284, 2013.
19. Buehler PW, Abraham B, Vallelian F, Linnemayr C, Pereira CP, Cipollo JF, Jia Y, Mikolajczyk M, Boretti FS, Schoedon G, et al.: Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood 113(11):2578-2586, 2009.
20. Hess JR, MacDonaldVW, BrinkleyWW: Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 74(4):1769-1778, 1993.
21. Winslow RM: Cell-free oxygen carriers: Scientific foundations, clinical development, and new directions. Biochim Biophys Acta 1784(10):1382-1386, 2008.
22. Lee R, Atsumi N, Jacobs EE Jr, Austen WG, Vlahakes GJ: Ultrapure, stromafree, polymerized bovine hemoglobin solution: Evaluation of renal toxicity. J Surg Res 47(5):407-411, 1989.
23. Gould SA, Sehgal LR, Rosen AL, Sehgal HL, Moss GS: The development of polymerized pyridoxylated hemoglobin solution as a red cell substitute. Ann Emerg Med 15(12):1416-1419, 1986.
24. Snyder SR, Welty EV, Walder RY, Williams LA, Walder JA: HbXL99 alpha: A hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. Proc Natl Acad Sci USA 84(20):7280-7284, 1987.
25. Looker D, Abbott-Brown D, Cozart P, Durfee S, Hoffman S, Mathews AJ, Miller-Roehrich J, Shoemaker S, Trimble S, Fermi G, et al.: A human recombinant haemoglobin designed for use as a blood substitute. Nature 356(366):258-260, 1992.
26. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD: No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 36(6):685-697, 2004.
27. Brillet T, Marden MC, Yeh JI, Shen TJ, Ho NT, Kettering R, Du S, Vasseur C, Domingues-Hamdi E, Ho C, et al.: Interaction of haptoglobin with hemoglobin octamers based on the mutation alphaAsn78Cys or betaGly83Cys. Am J Mol Biol 2(1):1-10, 2012.
28. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, Lemon DD: Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 16(7):672-676, 1998.
29. Dou Y, Maillett DH, Eich RF, Olson JS: Myoglobin as a model system for designing heme protein based blood substitutes. Biophys Chem 98(1-2):127-148, 2002.
30. Vandegriff KD, Olson JS: Morphological and physiological factors affecting oxygen uptake and release by red blood cells. J Biol Chem 259:12619-12627, 1984.
31. Lemon DD, Nair PK, Boland EJ, Olson JS, Hellums JD: Physiological factors affecting O2 transport by hemoglobin in an in vitro capillary system. J Appl Physiol 62(2):798-806, 1987.
32. Boland EJ, Nair PK, Lemon DD, Olson JS, Hellums JD: An in vitro capillary system for studies on microcirculatory O2 transport. J Appl Physiol 62(2):791-797, 1987.
33. Page TC, Light WR, McKay CB, Hellums JD: Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobinbased oxygen carrier performance. Microvasc Res 55(1):54-64, 1998.
34. Vandegriff KD: Chapter 5: The role of oxygen and hemoglobin diffusioin in oxygen transport by cell-free hemolgobins. In: Winslow R M, editor. Blood Substitutes. San Diego, CA: Academic Press; 2006. pp. 60-71.
35. Page TC, Hellums JD: Chapter 6: Oxygen transport properties of hemoglobinbased-oxygen-carriers: Studies using artificial capillaries and mathematical simulation. In: Winslow RM, editor. Blood Substitutes. San Diego, CA: Academic Press; 2006. pp. 72-83.
36. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM: Targeted O2 delivery by low-P50 hemoglobin: A new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol 285(4):H1411-H1419, 2003.
37. Olson JS, Phillips GN: Myoglobin discriminates between O2, NO, and CO by electrostatic interactions with the bound ligand. J Biol Inorg Chem 2(4):544-552, 1997.
38. Maillett DH, Simplaceanu V, Shen TJ, Ho NT, Olson JS, Ho C: Interfacial and distal-heme pocket mutations exhibit additive effects on the structure and function of hemoglobin. Biochemistry 47(40):10551-10563, 2008.
39. Birukou I, Schweers RL, Olson JS: Distal histidine stabilizes bound O2 and acts as a gate for ligand entry in both subunits of adult human hemoglobin. J Biol Chem 285(12):8840-8854, 2010.
40. Birukou I, Maillett DH, Birukova A, Olson JS: Modulating distal cavities in the alpha and beta subunits of human HbA reveals the primary ligand migration pathway. Biochemistry 50(34):7361-7374, 2011.
41. Campbell KL, Roberts JE, Watson LN, Stetefeld J, Sloan AM, Signore AV, Howatt JW, Tame JR, Rohland N, Shen TJ, et al.: Substitutions in woolly mammoth hemoglobin confer biochemical properties adaptive for cold tolerance. Nat Genet 42(6):536-540, 2010.
42. Noguchi H, Campbell KL, Ho C, Unzai S, Park SY, Tame JR: Structures of haemoglobin from woolly mammoth in liganded and unliganded states. Acta Crystallogr D Biol Crystallogr 68(Pt. 11):1441-1449, 2012.
43. Eich RF, Li T, Lemon DD, Doherty DH, Curry SR, Aitken JF, Mathews AJ, Johnson KA, Smith RD, Phillips GN Jr, et al.: Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 35(22):6976-6983, 1996.
44. Sakai H, Sou K, Horinouchi H, Kobayashi K, Tsuchida E: Review of hemoglobin-vesicles as artificial oxygen carriers. Artif Organs 33(2):139-145, 2009.
45. Sakai H, Horinouchi H, Tsuchida E, Kobayashi K: Hemoglobin vesicles and red blood cells as carriers of carbon monoxide prior to oxygen for resuscitation after hemorrhagic shock in a rat model. Shock 31(5):507-514, 2009.
46. Sakai H, Hara H, Yuasa M, Tsai AG, Takeoka S, Tsuchida E, Intaglietta M: Molecular dimensions of Hb-based O(2) carriers determine constriction of resistance arteries and hypertension. Am J Physiol Heart Circ Physiol 279(3):H908-H915, 2000.
47. Raat NJ, Liu JF, Doyle MP, Burhop KE, Klein J, Ince C: Effects of recombinanthemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med 145(1):21-32, 2005.
48. Jia Y, Buehler PW, Boykins RA, Venable RM, Alayash AI: Structural basis of peroxide-mediated changes in human hemoglobin: A novel oxidative pathway. J Biol Chem 282:4894-4907, 2007.
49. Buehler PW, Karnaukhova E, Gelderman MP, Alayash AI: Blood aging, safety, and transfusion: Capturing the "radical" menace. Antioxid Redox Signal 14(9):1713-1728, 2011.
50. Alayash AI: Oxidative pathways in the sickle cell and beyond. Blood Cells Mol Dis 70:78-86, 2018.
51. Alayash AI: Hemoglobin-based blood substitutes and the treatment of sickle cell disease: More harm than help Biomolecules 7(1): Pii: E2, 2017
52. Reeder BJ, Grey M, Silaghi-Dumitrescu RL, Svistunenko DA, Bulow L, Cooper CE, Wilson MT: Tyrosine residues as redox cofactors in human hemoglobin: Implications for engineering nontoxic blood substitutes. J Biol Chem 283(45):30780-30787, 2008.
53. Reeder BJ, Svistunenko DA, Cooper CE, Wilson MT: Engineering tyrosinebased electron flow pathways in proteins: The case of aplysia myoglobin. J Am Chem Soc 134(18):7741-7749, 2012.
54. Silkstone GG, Silkstone RS, Wilson MT, Simons M, Bulow L, Kallberg K, Ratanasopa K, Ronda L, Mozzarelli A, Reeder BJ, et al.: Engineering tyrosine electron transfer pathways decreases oxidative toxicity in hemoglobin: Implications for blood substitute design. Biochem J 473(19):3371-3383, 2016.
55. Silkstone RS, Silkstone G, Baath JA, Rajagopal B, Nicholls P, Reeder BJ, Ronda L, Bulow L, Cooper CE: The betaLys66Tyr variant of human hemoglobin as a component of a blood substitute. Adv Exp Med Biol 876:455-460, 2016.
56. Brooks J: The oxidation of haemoglobin to methaemoglobin by oxygen. Proc R Soc Lond 109:35-50, 1931.
57. Brooks J: The oxidation of haemoglobin to methaemoglobin by oxygen. II-the relation between the rate of oxidation and the partial pressure of oxygen. Proc R Soc Lond B Biol Sci 118:560-577, 1935.
58. Brooks J: The oxidation of haemoglobin to methaemoglobin by oxygen. J Physiol 107(3):332-335, 1948.
59. Wallace WJ, Houtchens RA, Maxwell JC, Caughey WS: Mechanism of autooxidation for hemoglobins and myoglobins. Promotion of superoxide production by protons and anions. J Biol Chem 257(9):4966-4977, 1982.
60. Shikama K: A controversy on the mechanism of autoxidation of oxymyoglobin and oxyhaemoglobin: Oxidation, dissociation, or displacement Biochem J 223(1):279-280, 1984.
61. Brantley RE Jr, Smerdon SJ, Wilkinson AJ, Singleton EW, Olson JS: The mechanism of autooxidation of myoglobin. J Biol Chem 268(10):6995-7010, 1993.
62. George P, Stratmann CJ: The oxidation of myoglobin to metmyglobin by oxygen. 2. The relation between the first order rate constant and the partial pressure of oxygen. Biochem J 51(3):418-425, 1952.
63. Wallace WJ, Maxwell JC, Caughey WS: The mechanisms of hemoglobin autoxidation. Evidence for proton-assisted nucleophilic displacement of superoxide by anions. Biochem Biophys Res Commun 57(4):1104-1110, 1974.
64. Weiss JJ: Nature of the iron-oxygen bond in oxyhaemoglobin. Nature 202:83-84, 1964.
65. Olson JS, Phillips GN Jr: Kinetic pathways and barriers for ligand binding to myoglobin. J Biol Chem 271(30):17593-17596, 1996.
66. Kakar S, Hoffman FG, Storz JF, FabianM, Hargrove MS: Structure and reactivity of hexacoordinate hemoglobins. Biophys Chem 152(1-3):1-14, 2010.
67. Zhang L, Levy A, Rifkind JM: Autoxidation of hemoglobin enhanced by dissociation into dimers. J Biol Chem 266(36):24698-24701, 1991.
68. Mollan TL, Jia Y, Banerjee S, Wu G, Kreulen RT, Tsai AL, Olson JS, Crumbliss AL, Alayash AI: Redox properties of human hemoglobin in complex with fractionated dimeric and polymeric human haptoglobin. Free Radic Biol Med 69:265-277, 2014.
69. MacQuarrie RA, Gibson QH: Functional heterogeneity of the alpha and beta chains in the oxidation-reduction reaction of human hemoglobin. J Biol Chem 246(2):517-522, 1971.
70. Tsuruga M, Matsuoka A, Hachimori A, Sugawara Y, Shikama K: The molecular mechanism of autoxidation for human oxyhemoglobin. Tilting of the distal histidine causes nonequivalent oxidation in the b chain. J Biol Chem 273(15):8607-8615, 1998.
71. Draghi F, Miele AE, Travaglini-Allocatelli C, Vallone B, Brunori M, Gibson QH, Olson JS: Controlling ligand binding in myoglobin by mutagenesis. J Biol Chem 277(9):7509-7519, 2002.
72. Olson JS, Ghosh A: Chapter 1: Mammalian myoglobin as a model for understanding ligand affinities and discrimination in heme proteins. In: Ghosh A, editor. The Smallest Biomolecules: Perspectives on Heme-Diatomic Interactions. London: Elsevier; 2007. pp. 2-17.
73. Carver TE, Brantley RE Jr, SingletonEW, Arduini RM, Quillin ML, Phillips GN Jr, Olson JS:A novel site-directed mutant of myoglobin with an unusually highO2 affinity and low autooxidation rate. J Biol Chem 267(20):14443-14450, 1992.
74. Wiltrout ME, Giovannelli JL, Simplaceanu V, Lukin JA, Ho NT, Ho C: A biophysical investigation of recombinant hemoglobins with aromatic B10 mutations in the distal heme pockets. Biochemistry 44(19):7207-7217, 2005.
75. Tam MF, Rice NW, Maillett DH, Simplaceanu V, Ho NT, Tam TC, Shen TJ, Ho C: Autoxidation and oxygen binding properties of recombinant hemoglobins with substitutions at the alphaVal-62 or betaVal-67 position of the distal heme pocket. J Biol Chem 288(35):25512-25521, 2013.
76. Hargrove MS, Olson JS: The stability of holomyoglobin is determined by heme affinity. Biochemistry 35(35):11310-11318, 1996.
77. Hargrove MS, Whitaker T, Olson JS, Vali RJ, Mathews AJ: Quaternary structure regulates hemin dissociation from human hemoglobin. J Biol Chem 272(28): 17385-17389, 1997.
78. Hargrove MS, Singleton EW, Quillin ML, Ortiz LA, Phillips GN Jr, Olson JS, Mathews AJ: His64(E7)!Tyr apomyoglobin as a reagent for measuring rates of hemin dissociation. J Biol Chem 269(6):4207-4214, 1994.
79. Hargrove MS, Wilkinson AJ, Olson JS: Structural factors governing hemin dissociation from metmyoglobin. Biochemistry 35(35):11300-11309, 1996.
80. Andersen CB, Torvund-Jensen M, Nielsen MJ, de Oliveira CL, Hersleth HP, Andersen NH, Pedersen JS, Andersen GR, Moestrup SK: Structure of the haptoglobin-haemoglobin complex. Nature 489(7416):456-459, 2012.
81. Samuel PP, Ou WC, Phillips GN Jr, Olson JS: Mechanism of human apohemoglobin unfolding. Biochemistry 56(10):1444-1459, 2017.
82. Samuel PP, Smith LP, Phillips GN Jr, Olson JS: Apoglobin stability is the major factor governing both cell-free and in vivo expression of holomyoglobin. J Biol Chem 290(39):23479-23495, 2015.
83. Bisse E, Schaeffer-Reiss C, Van Dorsselaer A, Alayi TD, Epting T, Winkler K, Benitez Cardenas AS, Soman J, Birukou I, Samuel PP, et al.: Hemoglobin Kirklareli (alpha H58L), a new variant associated with iron deficiency and increased CO binding. J Biol Chem 292(6):2542-2555, 2017.
84. McCarthy MR, Vandegriff KD, Winslow RM: The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: Implications for the design of hemoglobin-based oxygen carriers. Biophys Chem 92(1-2):103-117, 2001.
85. Chen JY, Scerbo M, Kramer G: A review of blood substitutes: Examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo) 64(8):803-813, 2009.
86. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM: Cell-free hemoglobinbased blood substitutes and risk of myocardial infarction and death: A metaanalysis. JAMA 299(19):2304-2312, 2008.
87. Gulati A, Singh G, Rebello S, Sharma AC: Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. Life Sci 56(17):1433-1442, 1995.
88. Vandegriff KD, Malavalli A, Minn C, Jiang E, Lohman J, Young MA, Samaja M, Winslow RM: Oxidation and haem loss kinetics of poly(ethylene glycol)-conjugated haemoglobin (MP4): Dissociation between in vitro and in vivo oxidation rates. Biochem J 399(3):463-471, 2006.
89. Katz LM, Manning JE, McCurdy S, Sproule C, McGwin G Jr, Moon-Massat P, Cairns CB, Freilich D: Nitroglycerin attenuates vasoconstriction of HBOC-201 during hemorrhagic shock resuscitation. Resuscitation 81(4):481-487, 2010.
90. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM: MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 43(4):509-516, 2003.
91. Abuchowski A: SANGUINATE (PEGylated carboxyhemoglobin bovine): Mechanism of action and clinical update. Artif Organs 41(4):346-350, 2017.
92. Abuchowski A, Sloshberg S, O'hare K: Hemoglobin Compositions. South Plainfield, NJ: Prolong Pharmaceuticals; 2010.
93. Hermann J, Corso C, Messmer KF: Resuscitation with recombinant hemoglobin rHb2.0 in a rodent model of hemorrhagic shock. Anesthesiology 107(2):273-280, 2007.